Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 30.43M 26.69M 24.64M 22.77M 43.16M 2.91B 44.03M 296M 115M 1.43B 114M 112M 4.95B P/E 2026 *
-1.15x
P/E 2027 * -1.73x
Enterprise Value 30.43M 26.69M 24.64M 22.77M 43.16M 2.91B 44.03M 296M 115M 1.43B 114M 112M 4.95B EV / Sales 2026 *
-
EV / Sales 2027 * 2.35x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-29 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-29 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-30 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
02-13 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day-7.62%
1 week-1.00%
Current month-1.02%
1 month-8.49%
3 months-17.09%
6 months-32.17%
Current year-28.68%
1 week 0.94
Extreme 0.9365
1.05
1 month 0.94
Extreme 0.9365
1.11
Current year 0.94
Extreme 0.9365
1.53
1 year 0.94
Extreme 0.9365
1.89
3 years 0.94
Extreme 0.9365
10.24
5 years 0.94
Extreme 0.9365
15.12
10 years 0.94
Extreme 0.9365
64.5
Manager TitleAgeSince
Chief Executive Officer 62 08/06/2017
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 71 31/12/2007
Chairman 62 30/09/2013
Director/Board Member 68 07/11/2013
Date Insider Type Main position Quantity % Market Cap.
17/08/25Tax

Chief Executive Officer

120,900 0.3876%
30/03/25Issuer sale

Director

184,984 0.5930%
30/03/25Issuer sale

Director

182,484 0.5850%
Change 5-day change 1-year change 3-year change Capi.($)
-7.62%-1.00%-32.17%-86.55% 30.43M
-1.10%-4.27%+69.89%+124.69% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+4.37%+3.68%+43.55%-2.16% 18.69B
-0.05%+0.99%+37.99%-25.93% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-1.50%+1.03%+35.05% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average -0.55%+4.33%+47.62%+126.56% 23.94B
Weighted average by Cap. -0.24%+2.20%+57.45%+143.30%

Financials

2026 *2027 *
Net sales - 12.93M 11.34M 10.47M 9.67M 18.33M 1.24B 18.7M 126M 48.89M 606M 48.54M 47.48M 2.1B
Net income -28.5M -25M -23.08M -21.33M -40.42M -2.73B -41.23M -277M -108M -1.34B -107M -105M -4.64B -23.27M -20.41M -18.84M -17.41M -33M -2.23B -33.66M -227M -88.01M -1.09B -87.38M -85.46M -3.78B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
08/07/26 US$0.9700 -7.62% 72,605
07/07/26 US$1.050 +9.26% 228,039
06/07/26 US$0.9610 -2.04% 144,720
02/07/26 US$0.9810 +0.12% 32,878
01/07/26 US$0.9798 -0.02% 93,296
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9700USD
Average target price
5.000USD
Spread / Average Target
+415.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock